• Join Today!

Become a member and connect with:

  • An Active Online Community
  • Articles and Advice on SCD
  • Help Understanding Clinical Trials
learn more
researchers

Richard Lottenberg, MD

Researcher
Professor Emeritus of Medicine
University of Florida College of Medicine
P.O. Box 100215
Gainesville, Florida, United States

Dr. Richard Lottenberg is a faculty member in the Department of Medicine at the University of Florida. He has previously served as Chief of the Division of Hematology/Oncology and Director of the Adult Sickle Cell Program. His research focus is in health services. He is currently a co-investigator of a multi- institutional NIH grant (Southeastern Exploratory Center of Excellence in Sickle Cell Disease).

Dr. Lottenberg leads the outreach core activity addressing the implementation and evaluation of primary care provider-based medical homes for the care of patients with sickle cell disease. His other research projects address the underuse of hydroxyurea therapy. He has been a member of the American Society of Hematology (ASH) committee on governmental Affairs since 2005 and leads the ASH Sickle Cell Disease Work group. He is on the NHLBI panel developing sickle cell disease clinical guidelines and serves as the team leader for the hydroxyurea therapy chapter.

view full profile

expertly curated content related to this topic

Don’t forget to join the oneSCDvoice community!

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close